Multi-center, pragmatic, cluster-randomized, controlled trial of standardized peritoneal dialysis (PD) training versus usual care on PD-related infections (the TEACH-PD trial): trial protocol
Josephine S. F. Chow,
Neil Boudville,
Yeoungjee Cho,
Suetonia Palmer,
Elaine M. Pascoe,
Carmel M. Hawley,
Donna M. Reidlinger,
Laura E. Hickey,
Ruth Stastny,
Andrea Valks,
Liza Vergara,
Ramya Movva,
Charani Kiriwandeniya,
Hayley Candler,
Gabor Mihala,
Bernadette Buisman,
Keri-Lu Equinox,
Ana E. Figueiredo,
Trudi Fuge,
Kirsten Howard,
Martin Howell,
Allison Jaure,
Matthew D. Jose,
Anna Lee,
Susana S. Miguel,
Jo-anne Moodie,
Thu T. Nguyen,
Geraldine Pinlac,
Annie Reynolds,
Walaa W. M. Saweirs,
Genevieve Z. Steiner-Lim,
Bronwen TeWhare,
Melinda Tomlins,
Megan Upjohn,
David Voss,
Rachael C. Walker,
Joanne Wilson,
David W. Johnson
Affiliations
Josephine S. F. Chow
South Western Sydney Local Health District
Neil Boudville
Medical School, University of Western Australia
Yeoungjee Cho
Department of Kidney and Transplant Service, Princess Alexandra Hospital
Suetonia Palmer
Department of Medicine, University of Otago
Elaine M. Pascoe
Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland
Carmel M. Hawley
Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland
Donna M. Reidlinger
Centre for Health Services Research, The University of Queensland
Laura E. Hickey
Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland
Ruth Stastny
Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland
Andrea Valks
Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland
Liza Vergara
Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland
Ramya Movva
Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland
Charani Kiriwandeniya
Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland
Hayley Candler
Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland
Gabor Mihala
Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland
Bernadette Buisman
Health New Zealand, Te Whatu Ora Te Tai Tokerau
Keri-Lu Equinox
Cairns Hospital
Ana E. Figueiredo
School of Nursing, Escola de Ciências da Saúde E da Vida, Pontifícia Universidade Católica Do Rio Grande Do Sul
Trudi Fuge
Kirsten Howard
Sydney School of Public Health, The University of Sydney
Martin Howell
Menzies Centre for Health Policy and Economics, Faculty of Medicine and Health, University of Sydney
Allison Jaure
Sydney School of Public Health, The University of Sydney
Matthew D. Jose
University of Tasmania
Anna Lee
Susana S. Miguel
South Western Sydney Local Health District
Jo-anne Moodie
Royal Melbourne Hospital
Thu T. Nguyen
Health New Zealand, Te Whatu Ora Te Toka Tumai
Geraldine Pinlac
Department of Medicine, University of Otago
Annie Reynolds
Health New Zealand, Te Whatu Ora Te Matua a Māui Hawkes Bay
Walaa W. M. Saweirs
Health New Zealand, Te Whatu Ora Te Tai Tokerau
Genevieve Z. Steiner-Lim
NICM Health Research Institute, Western Sydney University Sydney
Bronwen TeWhare
Health New Zealand, Te Whatu Ora Taranaki
Melinda Tomlins
Department of Nephrology, Hunter New England Local Health District
Megan Upjohn
Health New Zealand, Te Whatu Ora Te Toka Tumai
David Voss
Health New Zealand, Te Whatu Ora Counties Manukau
Rachael C. Walker
Te Pukenga Eastern Institute of Technology
Joanne Wilson
Department of Medicine, University of Otago
David W. Johnson
Department of Kidney and Transplant Service, Princess Alexandra Hospital
Abstract Background Peritoneal dialysis (PD)-related infections, such as peritonitis, exit site, and tunnel infections, substantially impair the sustainability of PD. Accordingly, PD-related infection is the top-priority research outcome for patients and caregivers. While PD nurse trainers teach patients to perform their own PD, PD training curricula are not standardized or informed by an evidentiary base and may offer a potential approach to prevent PD infections. The Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes (TEACH-PD) trial evaluates whether a standardized training curriculum for PD nurse trainers and incident PD patients based on the International Society for Peritoneal Dialysis (ISPD) guidelines reduces PD-related infections compared to usual training practices. Methods The TEACH-PD trial is a registry-based, pragmatic, open-label, multi-center, binational, cluster-randomized controlled trial. TEACH-PD will recruit adults aged 18 years or older who have not previously undergone PD training at 42 PD treatment units (clusters) in Australia and New Zealand (ANZ) between July 2019 and June 2023. Clusters will be randomized 1:1 to standardized TEACH-PD training curriculum or usual training practice. The primary trial outcome is the time to the first occurrence of any PD-related infection (exit site infection, tunnel infection, or peritonitis). The secondary trial outcomes are the individual components of the primary outcome, infection-associated catheter removal, transfer to hemodialysis (greater than 30 days and 180 days), quality of life, hospitalization, all-cause death, a composite of transfer to hemodialysis or all-cause death, and cost-effectiveness. Participants are followed for a minimum of 12 months with a targeted average follow-up period of 2 years. Participant and outcome data are collected from the ANZ Dialysis and Transplant Registry (ANZDATA) and the New Zealand Peritoneal Dialysis (NZPD) Registry. This protocol follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines. Discussion TEACH-PD is a registry-based, cluster-randomized pragmatic trial that aims to provide high-certainty evidence about whether an ISPD guideline-informed standardized PD training curriculum for PD nurse trainers and adult patients prevents PD-related infections. Trial registration ClinicalTrials.gov NCT03816111. Registered on 24 January 2019.